These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21617522)

  • 1. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
    Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 testing in gastric and gastroesophageal adenocarcinomas.
    Vakiani E
    Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
    Treacy AD; Karamchandani JR; Streutker CJ; Grin A
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 testing in gastric cancer: a practical approach.
    Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
    Jeung J; Patel R; Vila L; Wakefield D; Liu C
    Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.
    Nielsen SL; Nielsen S; Vyberg M
    Appl Immunohistochem Mol Morphol; 2017; 25(5):320-328. PubMed ID: 27801737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
    Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
    Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
    Boers JE; Meeuwissen H; Methorst N
    Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.